Zogenix

UCB sign

Pharma

Results for UCB's Fintepla pave way for 3rd epileptic indication

UCB plans to file for regulatory approval of Fintepla to treat a third epileptic condition “as soon as possible,” the company said.

Kevin Dunleavy Dec 8, 2025 11:19am

UCB's Fintepla shows potential to treat a 3rd epilepsy disorder

Jun 27, 2025 11:28am

epilepsy AI MRI

UCB pens multiple collabs to boost cluster seizure awareness

Aug 22, 2022 3:00pm

Dementia

UCB nabs Fintepla label expansion

Mar 28, 2022 9:18am

UCB sign

2 players vied before UCB emerged to buy Zogenix for $1.9B

Feb 1, 2022 5:24pm

UCB sign

UCB bolsters epilepsy portfolio with Zogenix buy

Jan 19, 2022 11:16am